/ALSEN.PA

ALSEN.PA Stock - Sensorion S.A.

Q: What is the analyst price target for ALSEN.PA?

Analyst price target information is not currently available for ALSEN.PA.

Q: What is ALSEN.PA's market cap?

Market capitalization information is not currently available for ALSEN.PA.

Healthcare|Biotechnology|PAR

$0.32-1.84%

$0.01 (-1.84%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.35

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for ALSEN.PA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.59

52W High$0.71

52W Low$0.15

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$6.65M	$5.70M	$4.93M	$4.26M	$2.35M
Gross Profit	$6.65M	$3.79M	$4.16M	$3.75M	$1.94M
Gross Margin	100.0%	66.5%	84.4%	88.0%	82.3%
Operating Income	$-28,401,000	$-22,310,628	$-28,104,820	$-19,350,260	$-11,290,110
Net Income	$-25,972,000	$-22,063,404	$-23,209,090	$-15,136,789	$-8,978,089
Net Margin	-390.4%	-387.2%	-470.4%	-355.0%	-381.7%
EPS	$-0.09	$-0.17	$-0.29	$-0.19	$-0.15

Company Overview

Sensorion SA, a clinical-stage biopharmaceutical company, develops drug candidates for the treatment of inner ear disorders in France. The company develops OTOF-GT, a gene therapy development program to restore hearing in people living with Otoferlin deficiency; USHER-T1-GT, a gene therapy development program to for patients suffering from usher syndrome Type 1; and SENS-401, a drug candidate to treat sudden sensorineural hearing loss. Its pipeline also includes various products in development stage for restoring, treating, and preventing inner ear related disorders. The company has a collaboration agreement with Institut Pasteur for gene therapy program for pediatric and adult deafness; and with Sonova Holding AG to introduce genetic analysis for routine diagnosis of progressive hearing loss in adults through a combination of advanced therapeutic interventions and traditional hearing aids. Sensorion SA was founded in 2009 and is headquartered in Montpellier, France.

Visit Website

Earnings History & Surprises

ALSEN.PA

Beat Rate

71%

Last 7 quarters

Avg Surprise

+25.0%

EPS vs Estimate

Beats / Misses

5/2

Last 12 quarters

Latest EPS

$-0.05

Q3 2025

EPS Surprise History

Q2 22

No data

Q3 22

No data

Q2 23

-24.6%

$-0.14vs$-0.11

Q3 23

+99.9%

$-0.15vs$-144.00

Q1 24

+34.7%

$-0.05vs$-0.08

Q3 24

+12.4%

$-0.05vs$-0.06

Q1 25

+20.4%

$-0.04vs$-0.05

Q3 25

-6.6%

$-0.05vs$-0.05

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 12, 2026	—	—	—	—
Q3 2025	Sep 17, 2025	$-0.05	$-0.05	-6.6%	✗ MISS
Q1 2025	Mar 12, 2025	$-0.05	$-0.04	+20.4%	✓ BEAT
Q3 2024	Sep 18, 2024	$-0.06	$-0.05	+12.4%	✓ BEAT
Q1 2024	Mar 14, 2024	$-0.08	$-0.05	+34.7%	✓ BEAT
Q3 2023	Sep 20, 2023	$-144.00	$-0.15	+99.9%	✓ BEAT
Q2 2023	Jun 7, 2023	$-0.11	$-0.14	-24.6%	✗ MISS
Q3 2022	Aug 14, 2022	—	$-0.15	—	—
Q2 2022	May 14, 2022	—	$-0.11	—	—
Q3 2021	Sep 27, 2021	$-0.13	$-0.08	+38.5%	✓ BEAT
Q1 2021	Mar 18, 2021	—	$-0.06	—	—
Q4 2020	Oct 21, 2020	—	$-0.09	—	—
Q2 2020	Apr 2, 2020	—	$-0.25	—	—
Q4 2019	Nov 1, 2019	—	$-0.40	—	—
Q1 2019	Mar 27, 2019	—	$-0.48	—	—
Q4 2018	Oct 18, 2018	—	$-0.62	—	—
Q2 2018	Apr 12, 2018	—	$-0.69	—	—
Q4 2017	Oct 19, 2017	—	$-0.66	—	—
Q1 2017	Mar 14, 2017	—	$-0.43	—	—
Q4 2016	Oct 15, 2016	—	$-0.68	—	—